Open access
Oct 2026
TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer.
CLINICAL TRIAL REGISTRATION NCT06966700 (ClinicalTrials.gov); EU CT 2024-520190-12 (EudraCT).
P. Schmid, Javier Cortés, R. Hui et al.
· Future Oncology · 0 citations